Power your research and clinical trials
Research into the role of fluid-based biomarkers for the assessment of brain amyloid beta (Aβ) pathology is quickly advancing the understanding of Alzheimer’s disease and related dementias. As fluid-based biomarkers redefine how Alzheimer’s disease is diagnosed — and how individuals are enrolled in clinical trials — incorporation of fluid biomarkers into clinical studies is crucial.
Mayo Clinic Laboratories BioPharma Diagnostics’ industry-leading biomarker testing for Alzheimer’s disease and related dementias can help investigators advance research and discovery.
In this digital guide, you’ll learn:
- The evolution of blood biomarker testing
- How testing results from these evaluations power your research and clinical trials
- Comprehensive testing options for dementias and other neurodegenerative disorders
Offered Free by: Mayo Clinic Laboratories
See All Resources from: Mayo Clinic Laboratories
